Healthcare and Medical

Fibromyalgia Treatment Market Growth Outlook Through 2024-2033

Uday Kiran

Fibromyalgia Treatment Market Growth Outlook Through 2024-2033

The fibromyalgia treatment market size is expected to see steady growth in the next few years. It will grow to $3.28 billion in 2028 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to growing geriatric population, rising healthcare expenditure, rising occurrence of musculoskeletal disorders, increasing research and development activities to develop better treatment. Major trends in the forecast period include advancements in treatment options, strategic collaborations, advancements in integration of technology, innovative treatments.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Segmentation & Regional Insights

The fibromyalgia treatment market covered in this report is segmented –

1) By Type: Symptomatic Treatment; Targeted Treatment

2) By Drug Class: Antidepressants; Antiepileptics; Muscle Relaxants; Analgesics; Other Drugs

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

North America was the largest region in the fibromyalgia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fibromyalgia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12933&type=smp

Major Driver Impacting Market Growth

Rising government initiatives on musculoskeletal conditions are expected to propel the growth of the fibromyalgia market going forward. Government initiatives refer to specific actions, policies, programs, or projects undertaken by a government to address various societal issues, promote economic growth, improve public services, or achieve particular goals that benefit the nation and its citizens. Major government authorities are implementing several initiatives to help patients suffering from musculoskeletal conditions. For instance, in 2022, according to Musculoskeletal Australia, an Australia-based organization, the Australian government implemented the Own Your Health initiative. This initiative strives for overall self-care for patients suffering from musculoskeletal conditions for the next four years. Therefore, rising government initiatives on musculoskeletal conditions drive the fibromyalgia market.

Key Industry Players

Major players in the fibromyalgia treatment market are Pfizer Inc., Johnson and Johnson Services Inc., Roche Holding AG, AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Endo International PLC, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Lupin Limited.

The fibromyalgia treatment market report table of contents includes: